Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine.

Larsen JR, Svensson CK, Vedtofte L, Jakobsen ML, Jespersen HS, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Holst JJ, Correll CU, Vilsbøll T, Fink-Jensen A.

CNS Spectr. 2018 Dec 31:1-12. doi: 10.1017/S1092852918001311. [Epub ahead of print]

PMID:
30596361
2.

One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.

Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A.

Acta Psychiatr Scand. 2019 Jan;139(1):26-36. doi: 10.1111/acps.12982. Epub 2018 Nov 28.

PMID:
30374965
3.

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.

Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A.

JAMA Psychiatry. 2017 Jul 1;74(7):719-728. doi: 10.1001/jamapsychiatry.2017.1220.

4.

The significance of sampling time in therapeutic drug monitoring of clozapine.

Jakobsen MI, Larsen JR, Svensson CK, Johansen SS, Linnet K, Nielsen J, Fink-Jensen A.

Acta Psychiatr Scand. 2017 Feb;135(2):159-169. doi: 10.1111/acps.12673. Epub 2016 Dec 6.

PMID:
27922183
5.

What Should Constitute an Acceptable Advanced Pharmacy Practice Experience?

Svensson CK.

Am J Pharm Educ. 2016 Apr 25;80(3):37. doi: 10.5688/ajpe80337. No abstract available.

6.

Fabry disease, respiratory symptoms, and airway limitation - a systematic review.

Svensson CK, Feldt-Rasmussen U, Backer V.

Eur Clin Respir J. 2015 Jun 26;2. doi: 10.3402/ecrj.v2.26721. eCollection 2015. Review.

7.

Should a pharmacy dean be a pharmacist?

Svensson CK.

Am J Pharm Educ. 2015 Apr 25;79(3):32. doi: 10.5688/ajpe79332. No abstract available.

8.

Pharmacogenomics of acetaminophen in pediatric populations: a moving target.

Krasniak AE, Knipp GT, Svensson CK, Liu W.

Front Genet. 2014 Oct 14;5:314. doi: 10.3389/fgene.2014.00314. eCollection 2014. Review.

9.

Assessing quality in pharmacy education in an era of rapid expansion: response to Maine and Vlasses.

Popovich NG, Robert L M, Roberts JC, Svensson CK, Sullivan DL.

J Am Pharm Assoc (2003). 2013 May-Jun;53(3):228, 232. doi: 10.1331/JAPhA.2013.12182. No abstract available.

PMID:
23699669
10.

Advancing pharmacist scholarship and research within academic pharmacy.

Kehrer JP, Svensson CK.

Am J Pharm Educ. 2012 Dec 12;76(10):187. doi: 10.5688/ajpe7610187.

11.

Maintaining pharmacy education's research focus as the academy expands.

Bauman JL, Ascione FJ, Brueggemeier RW, Letendre DE, Roberts JC, Speedie MK, Svensson CK.

Am J Pharm Educ. 2012 Oct 12;76(8):144. doi: 10.5688/ajpe768144. No abstract available.

12.

Are we producing innovators and leaders or change resisters and followers?

Svensson CK, Ascione FJ, Bauman JL, Brueggemeier RW, Letendre DE, Roberts JC, Speedie MK.

Am J Pharm Educ. 2012 Sep 10;76(7):124. doi: 10.5688/ajpe767124. No abstract available.

13.

Reconsidering the length of program accreditation.

Svensson CK, Speedie MK, Roberts JC, Letendre DE, Brueggemeier RW, Bauman JL, Ascione FJ.

Am J Pharm Educ. 2011 Feb 10;75(1):6. No abstract available.

14.

Commentary: current advances and future directions for CNS delivery.

Svensson CK, Scherrmann JM.

AAPS J. 2008 Dec;10(4):587-8. doi: 10.1208/s12248-008-9064-1. Epub 2008 Dec 12. No abstract available.

15.

Biotransformation of drugs in human skin.

Svensson CK.

Drug Metab Dispos. 2009 Feb;37(2):247-53. doi: 10.1124/dmd.108.024794. Epub 2008 Nov 12.

PMID:
19005027
16.

Effect of arylhydroxylamine metabolites of sulfamethoxazole and dapsone on stress signal expression in human keratinocytes.

Khan FD, Vyas PM, Gaspari AA, Svensson CK.

J Pharmacol Exp Ther. 2007 Dec;323(3):771-7. Epub 2007 Aug 31.

PMID:
17766678
17.

Detection of haptenated proteins in organotypic human skin explant cultures exposed to dapsone.

Roychowdhury S, Cram AE, Aly A, Svensson CK.

Drug Metab Dispos. 2007 Sep;35(9):1463-5. Epub 2007 Jun 6.

PMID:
17553916
18.

Formation and uptake of arylhydroxylamine-haptenated proteins in human dendritic cells.

Roychowdhury S, Vyas PM, Svensson CK.

Drug Metab Dispos. 2007 Apr;35(4):676-81. Epub 2007 Jan 12.

PMID:
17220235
19.

Immune response to xenobiotics in the skin: from contact sensitivity to drug allergy.

Khan FD, Roychowdhury S, Gaspari AA, Svensson CK.

Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):261-72. Review.

PMID:
16866612
20.

Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450.

Vyas PM, Roychowdhury S, Khan FD, Prisinzano TE, Lamba J, Schuetz EG, Blaisdell J, Goldstein JA, Munson KL, Hines RN, Svensson CK.

J Pharmacol Exp Ther. 2006 Oct;319(1):488-96. Epub 2006 Jul 20.

PMID:
16857728
21.

Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: II. Expression and role of flavin-containing monooxygenases and peroxidases.

Vyas PM, Roychowdhury S, Koukouritaki SB, Hines RN, Krueger SK, Williams DE, Nauseef WM, Svensson CK.

J Pharmacol Exp Ther. 2006 Oct;319(1):497-505. Epub 2006 Jul 20.

PMID:
16857727
22.

Drug hypersensitivity--where do we stand?

Svensson CK.

AAPS J. 2006;8(2):E236-8. No abstract available.

23.

Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts.

Bhaiya P, Roychowdhury S, Vyas PM, Doll MA, Hein DW, Svensson CK.

Toxicol Appl Pharmacol. 2006 Sep 1;215(2):158-67. Epub 2006 Apr 17.

24.

Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin.

Roychowdhury S, Svensson CK.

AAPS J. 2005 Dec 9;7(4):E834-46. Review.

25.

Enhanced xenobiotic-induced hepatotoxicity and Kupffer cell activation by restraint-induced stress.

Panuganti SD, Khan FD, Svensson CK.

J Pharmacol Exp Ther. 2006 Jul;318(1):26-34. Epub 2006 Mar 28.

PMID:
16569754
26.

Effect of pro-inflammatory cytokines on the toxicity of the arylhydroxylamine metabolites of sulphamethoxazole and dapsone in normal human keratinocytes.

Khan FD, Roychowdhury S, Nemes R, Vyas PM, Woster PM, Svensson CK.

Toxicology. 2006 Feb 1;218(2-3):90-9. Epub 2005 Nov 14.

PMID:
16289751
27.

Role of human cyclooxygenase-2 in the bioactivation of dapsone and sulfamethoxazole.

Vyas PM, Roychowdhury S, Svensson CK.

Drug Metab Dispos. 2006 Jan;34(1):16-8. Epub 2005 Oct 7.

PMID:
16214851
29.

Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes.

Roychowdhury S, Vyas PM, Reilly TP, Gaspari AA, Svensson CK.

J Pharmacol Exp Ther. 2005 Jul;314(1):43-52. Epub 2005 Mar 22.

PMID:
15784651
30.

Do arylhydroxylamine metabolites mediate idiosyncratic reactions associated with sulfonamides?

Svensson CK.

Chem Res Toxicol. 2003 Sep;16(9):1035-43. Review. No abstract available.

PMID:
12971790
31.

Beta-glucuronidase activity in patients infected with HIV.

O'Neil WM, Drobitch RK, MacArthur RD, Farrough MJ, Crane LR, Svensson CK.

AIDS. 2003 Jan 24;17(2):269-70. No abstract available.

PMID:
12545091
32.

Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity.

O'Neil WM, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, Crane LR, Svensson CK.

J Clin Pharmacol. 2002 Jun;42(6):613-9.

PMID:
12043950
33.

Cutaneous drug reactions.

Svensson CK, Cowen EW, Gaspari AA.

Pharmacol Rev. 2001 Sep;53(3):357-79. Review.

PMID:
11546834
34.

A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions.

Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, Svensson CK.

J Invest Dermatol. 2000 Jun;114(6):1164-73.

35.

Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype.

O'Neil WM, Drobitch RK, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, Crane LR, Svensson CK.

Pharmacogenetics. 2000 Mar;10(2):171-82.

PMID:
10762005
36.

Is hydroxylamine-induced cytotoxicity a valid marker for hypersensitivity reactions to sulfamethoxazole in human immunodeficiency virus-infected individuals?

Reilly TP, MacArthur RD, Farrough MJ, Crane LR, Woster PM, Svensson CK.

J Pharmacol Exp Ther. 1999 Dec;291(3):1356-64.

PMID:
10565861
37.

Cellular distribution of N-acetyltransferase activity in the rat small intestine.

Ware JA, Reilly TP, Svensson CK.

Biochem Pharmacol. 1998 May 1;55(9):1475-9.

PMID:
10076540
38.
39.

Comparison of the in vitro cytotoxicity of hydroxylamine metabolites of sulfamethoxazole and dapsone.

Reilly TP, Bellevue FH 3rd, Woster PM, Svensson CK.

Biochem Pharmacol. 1998 Mar 15;55(6):803-10.

PMID:
9586952
40.

Effect of streptolysin-O-on rat hepatic acetyl coenzyme-A: arylamine N-acetyltransferase and cytochrome P-450 2B 1/2 activities ex vivo.

Drobitch RK, Divakaruni P, Svensson CK.

Immunopharmacol Immunotoxicol. 1998 Feb;20(1):159-71.

PMID:
9543706
41.

Acetyl CoA:arylamine N-acetyltransferase activity in rat hepatocytes cultured on different extracellular matrices.

Zaher H, Lindblad WJ, Jiang W, Doll MA, Hein DW, Svensson CK.

Toxicol In Vitro. 1997 Jun;11(3):271-83.

PMID:
20654313
42.
45.

Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy.

Tisdale JE, Rudis MI, Padhi ID, Borzak S, Svensson CK, Webb CR, Acciaioli J, Ware JA, Krepostman A, Zarowitz BJ.

J Clin Pharmacol. 1996 Jan;36(1):35-41.

PMID:
8932541
46.

Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans.

Tisdale JE, Rudis MI, Padhi ID, Svensson CK, Webb CR, Borzak S, Ware JA, Krepostman A, Zarowitz BJ.

J Clin Pharmacol. 1995 Sep;35(9):902-10.

PMID:
8786250
47.

Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains.

Ware JA, Divakaruni P, Svensson CK.

Drug Metab Dispos. 1995 Feb;23(2):295-7. No abstract available.

PMID:
7736928
48.
50.

Glucocorticoid induction of hepatic acetyl CoA:arylamine N-acetyltransferase activity in the rat.

Zaher H, Svensson CK.

Res Commun Chem Pathol Pharmacol. 1994 Feb;83(2):195-208.

PMID:
8202632

Supplemental Content

Loading ...
Support Center